Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.55 |
| ▸ | CA2 | P00918 | 2/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14907235 | 1.00 | CA1 (0.55) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL1521784 | 1.00 | CA1 (0.55) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL2101944 | 1.00 | CA1 (0.55) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL13565616 | 1.00 | CA1 (0.55) | CA1CA2POLBTSHRKMT2A | |
| Hydrochloric Acid SCHEMBL16830708 | 0.97 | CA1 (0.52) | CA1CA2POLBTSHRKMT2A | |
| Ammonia Solution, Strong SCHEMBL4301662 | 0.97 | CA1 (0.52) | CA1CA2POLBTSHRKMT2A | |
| SCHEMBL12988565 | 0.97 | — | — | |
| SCHEMBL171574 | 0.97 | — | — | |
| SCHEMBL3123076 | 0.90 | — | — | |
| SCHEMBL12989189 | 0.90 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024564-A1 | SMALL MOLECULES THAT PREVENT STATIN-INDUCED ACCUMULATION OF HMG COA REDUCTASE | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2025-01-30 | — | — | WO | claimed |
| EP-4100408-B1 | TRICYCLIC HETEROARYL COMPOUNDS USEFUL AS IRAK4 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2024-02-28 | — | — | EP | claimed |
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-18 | — | — | US | claimed |
| CN-114126713-B | Substituted benzimidazolone compounds | 百时美施贵宝公司 | 2023-12-08 | — | — | CN | claimed |
| WO-2023209441-A1 | IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS | LEGOCHEM BIOSCIENCES, INC. (KR) | 2023-11-02 | — | — | WO | claimed |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | NOVARTIS AG (CH) | 2023-10-17 | — | — | US | claimed |
| EP-4255906-A1 | NEW INDAZOLE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2023-10-11 | — | — | EP | claimed |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | ANIMA BIOTECH INC. (US) | 2023-07-06 | — | — | US | claimed |
| EP-4161921-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | Anima Biotech Inc. (US) | 2023-04-12 | — | — | EP | claimed |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | NOVARTIS AG (CH) | 2023-04-06 | — | — | US | claimed |
| CN-100413861-C | Compounds and methods for the treatment or prevention of flavivirus infections | VIROCHEM PHARMA INC (CA) | 2008-08-27 | — | — | CN | claimed |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2008-05-22 | — | — | US | claimed |
| US-7348331-B2 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC (US) | 2008-03-25 | — | — | US | claimed |
| EP-1343771-B1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LTD (GB) | 2006-04-12 | — | — | EP | claimed |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | ROCHE PALO ALTO LLC | 2005-05-19 | — | — | US | claimed |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | DATTA USA (GB) | 2004-07-22 | — | — | US | claimed |
| EP-1343771-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | Pfizer Limited (GB) | 2003-09-17 | — | — | EP | claimed |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | PFIZER, INC | 2002-10-17 | — | — | US | claimed |
| WO-2002050046-A1 | 3-OX(ADI)AZOLYLPROPANOHYDROXAMIC ACIDS USEFUL AS PROCOLLAGEN C-PROTEINASE INHIBITORS | PFIZER LIMITED (GB) | 2002-06-27 | — | — | WO | claimed |
| CN-1035179-C | New indol derivatives | ALMIRALL LAB (ES) | 1997-06-18 | — | — | CN | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240018154-A1 | NEW INDAZOLE DERIVATIVES | CYP3A43, CYP3A4, CYP3A5 | CA1 3092/4885CA2 1293/4885POLB 4605/4885 |
| US-20080119497-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | CA1 4866/4885CA2 4720/4885POLB 1085/4885 |
| US-11787785-B2 | Pyrazolopyridine derivatives and uses thereof | HBZ, ZFX, WIZ | CA1 4813/4885CA2 3395/4885POLB 981/4885 |
| US-20230212131-A1 | COLLAGEN 1 TRANSLATION INHIBITORS AND METHODS OF USE THEREOF | COL1A1, COL2A1, COL14A1 | CA1 4669/4885CA2 4469/4885POLB 554/4885 |
| US-20020151535-A1 | 3-ox(adi) azolylpropanohydroxamic acids useful as procollagen C- Proteinase inhibitors | ALPI, TIMP3, MMP1 | CA1 127/4885CA2 184/4885POLB 3127/4885 |
| US-20050107408-A1 | Hydroxyalkyl substituted pyrido-7-pyrimidin-7-ones | MAPK1, MAPK7, MAPK6 | CA1 4866/4885CA2 4720/4885POLB 1085/4885 |
| US-20230108325-A1 | Pyrazolopyridine Derivatives and Uses thereof | HBZ, ZFX, WIZ | CA1 4813/4885CA2 3395/4885POLB 981/4885 |
| US-20040142986-A1 | 3-ox(adi)azolylpropanohydroxamic acids useful as procollagen C-proteinase inhibitors | ALPI, TIMP3, MMP1 | CA1 127/4885CA2 184/4885POLB 3127/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.